ABOUT

ASCORBICO was founded by Mr. Ofer Taran and Moshe Nissim

Ofer Taran - Ascorbico Founder & CEO

was Ofer Taran is a B.Sc. Electrical  & Electronics Engineer from Tel Aviv University and holds a

marketing diploma from Xerox South Africa. Mr. Taran has served many years in the High-tech

industry, covering wide aspects of engineering, sales, marketing and business development,

including 3 years as head of Orbot U.K. branch, followed by long service in several start-up

companies in Israel, including 4 years in A.T.I technological incubator platform, performing the

role of business development, in the life science arena. In addition, Mr. Taran serves as Israel's

Director of G.I.C Group - a U.S. Agriculture investment banking group.

Ascorbico Ltd. Is a young but ambitious Biotechnology / Food startup who has researched and developed a state-of-the-art Food ( not a supplementary food ) that provides a therapeutic solution to two of the world devastating diseases. Based on thorough ChatGPT investigation this Formulation, is a U.S.P.T.O provisionally  patented and in a post proof-of-concept stage, following successful and encouraging  small scale preliminary clinical studies results, intended to address the most challenging  risks world health sector is facing now – Obesity and  Diabetes Type 2 . Ascorbico strives to make a firm commitment to both food the health sectors and we are ready to share our contribution with leading players in this field by taking the project to the next level. And embark on full scale human trials, followed collaboration with a strategic partner.

Due the nature of this business, given the magnitude of current world demand for therapeutic solution to Diabetes Type 1 & 2 on one hand and the tremendous efforts world health authorities investing in providing medical solutions to Obesity including  increasing public awareness of all age groups on the other, it is unrealistic at this stage to envisage or predict quantities with respect to sales of Ascorbico’s future products, or the diversity of its platform. 

This novel invention can transpire into an unprecedented scale and diversity by any standard and could reach tens of billions of $ U.S. per year from year 3 nevertheless, it requires biotechnology, engineering and marketing decisions based on a new set of priorities.